Cencora, Inc. (NYSE: COR) reported fiscal fourth-quarter and full-year results for 2026 and raised its quarterly dividend 10 percent to $0.66 per share. The pharmaceutical distributor posted full-year revenue of $337.4 billion and said the higher payout reflects continued cash generation across its core drug distribution business.
The setup
The board declared the new dividend on November 3, 2026. The payment is scheduled for November 30 to shareholders of record on November 13. The annualized payout rises to $2.64 per share, up from $2.40, and marks the third consecutive year Cencora has increased its dividend.
The increase came alongside fiscal 2026 earnings that showed the company expanding revenue while managing tight drug-distribution margins. Investors looking at large-cap healthcare distributors often treat these names as income-growth proxies within the broader healthcare supply chain.
Key numbers
| Metric | Fiscal Q4 2026 | Fiscal full year 2026 |
|---|---|---|
| Revenue | $88.4 billion | $337.4 billion |
| Revenue growth | +5.5% | +5.0% |
| GAAP diluted EPS | $2.71 | $17.95 |
| Adjusted diluted EPS | $4.66 | $17.97 |
| Adjusted EPS growth | +21.4% vs prior year quarter | +12.3% |
| New quarterly dividend | $0.66 | — |
| Annualized dividend | $2.64 | — |
| Forward yield at ~$340.50 | ~0.77% | — |
| Earnings payout ratio | ~14% | ~15% |
What to watch
Cencora also announced an agreement to acquire American Oncology Network, a physician-led network of more than 350 oncology providers across 21 states. The deal would deepen its presence in specialty distribution and could change the company’s margin profile over time.
The planned sale of the company’s stake in Profarma is expected to close in the first quarter of fiscal 2027. That divestiture, plus any integration costs from the oncology acquisition, will affect free cash flow available for future dividend growth. The payout ratio remains low, which gives the board room, but distribution margins are thin and regulatory scrutiny of drug pricing persists.
Bottom line
Cencora’s 10 percent dividend hike is supported by modest revenue growth and strong adjusted earnings expansion. The yield is below 1 percent, so this is not a high-income stock, but the low payout ratio and multi-year increase record make it a dividend-growth candidate for healthcare-focused portfolios.
What $100,000 invested in Cencora produces
At a share price near $340.50, a $100,000 stake buys approximately 294 shares. The new annual dividend of $2.64 per share would generate roughly $776 in yearly income before taxes. That is a modest current yield, but the low payout ratio means the dividend is well covered by earnings.
| Investment amount | Approximate shares at $340.50 | Annual dividend income |
|---|---|---|
| $100,000 | 294 | ~$776 |
| $250,000 | 734 | ~$1,938 |
Analysts focus on specialty growth and margins
Analysts following Cencora generally view the American Oncology Network acquisition as a way to expand specialty-pharmacy revenue and improve margins over time. The same analysts caution that traditional drug-distribution margins remain thin and that political pressure on drug pricing could limit pricing power.
The consensus expectation is for adjusted earnings to grow at a mid-teens percentage rate in fiscal 2027, which would provide additional coverage for another dividend increase if management chooses to raise the payout.
Stay ahead with our weekly newsletter
Get stock picks, market analysis, and strategy updates delivered to your inbox every week.
Subscribe to AlphaBetaStock’s free newsletter for daily market insights.
